Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

202394 citationsJournal Article

Authors

Marion van Mackelenbergh

Sibylle Loibl · German Breast group

Michael Untch · Helios Kliniken

Marc Buyse · International Drug Development Institute (Belgium)

Charles E. Geyer · University of Pittsburgh

Luca Gianni · San Raffaele University of Rome

Andreas Schneeweiß · National Center for Tumor Diseases

Abstract

These results confirm that patients achieving pCR have far better survival outcomes than patients who do not. The traditional poor prognostic features, namely tumor size and nodal status, remain important even after a pCR.

Topics & Keywords

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 16, pp. 2998-3008

DOI: 10.1200/jco.22.02241

Field-Weighted Citation Impact: 22.36